semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type1 Diabetes Mellitus Adults ≥18 years of age Diagnosis of T1DM for > 1 year On MDI using a basal-bolus insulin regime or CSII (insulin pump) for at least 6 months Structured education done and good ability perform CHO counting HbA1c ≥ 48mmol/mol and ≤ 86mmol/mol Using ICR and ISF to calculate the mealtime bolus An understanding of and willingness to follow the protocol and sign the informed consent CBG measurements at least 2 times per day for calibration of the CGM  Severe episode of hypoglycaemia (requiring 3rd party assistance) in the6 months prior to enrolment Diabetic ketoacidosis in the last 6 months prior to enrolment Impaired awareness of hypoglycaemia (based on Gold score) Pregnancy, breastfeeding or intention of becoming pregnant over time of study procedures Enrolled in other clinical trials Have active malignancy or under investigation for malignancy Suspected or diagnosed endocrinopathy like adrenal insufficiency, unstable thyroidopathy, endocrine tumour Gastroparesis Autonomic neuropathy Macrovascular complications (acute coronary syndrome, transient ischaemic attack, cerebrovascular event within the last 12 months prior to enrolment in the study)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure Type 2 Diabetes HbA1c> 6.5% Estimated GF> 45 ml / min BMI: ≥25 Kg / m2 Stable pharmacological treatment of Heart Failure in the last 3 months  Diabetes type 1 or type LADA (presence of antibodies against GAD and/or IA-2 positive) DM2 with C-peptide <1 ng / mL GEF <45 ml / min Recurrent urinary tract infections
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Asthma-COPD Overlap Syndrome Vitamin D Deficiency Cardiac Autonomic Tone • 40-80 years of age Male Middle class of socioeconomic condition Stable patients of Asthma COPD Overlap (ACO) with >4 years of disease duration Vitamin D deficient (Serum 25-hydroxycholecalciferol, 25(OH)D level < 30 ng/ml) Normal serum Ca+and inorganic phosphate level Hypertension with ACO Diabetes with ACO  Unstable patients with ACO (patients with exacerbation and medication changes in the past 30 days) With acute exacerbation of any pulmonary diseases, such as Bronchial asthma Acute respiratory tract infection Current tuberculosis Pleural effusion Emphysematous bullae Interstitial lung disease Pneumonectomy or pulmonary lobectomy Pulmonary fibrosis
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 60.0-80.0,  Vitamin D Deficiency Postmenopausal Caucasian Total plasma 25-hydroxy vitamin D < 50 nmol/L Understand oral and written Danish Able to consent  Known allergic reaction/intolerance to Vitamin D supplementation / milk products / juice Known chronic kidney disease (creatinine > 90 µmol/L), previous kidney transplantation or known kidney artery stenosis Known liver disease Known gastrointestinal malabsorption Current malignant disease Hypercalcemia (ionised calcium ≥ 1.33 mmol/L) Treatment with diuretics, lithium or current use of steroids Current use of calcium and/or vitamin D supplementation Planned travel during the intervention period to areas where sun exposure is expected Use of solarium
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 35.0-70.0,  Dyslipidemia Associated With Type II Diabetes Mellitus type II diabetic patients with hypercholesterolemia  liver impairment renal insufficiency coronary artery disease metabolic disorders type I diabetes autoimmune diseases, cancer, infection use of anti-inflammatory drugs recent major surgery weight-loss or modified anti-hypertensive medications 12 weeks or less prior to enrolment ongoing or previous use of lipid-lowering medications (including other statins, fibric acid derivatives, nicotinic acid, cholestyramine, ezetimibe or omega-3 fatty acids) and contraindications to the use of statins
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Adrenergic Beta-Antagonists Stable Angina Pectoris Medication Adherence Mobile Applications Aged 18-70 years; 2. Stable angina pectoris; 3. Indicated for beta blockers; 4. HR ≥ 60bpm; 5. Patient must have a smart phone that is compatible with the Patient support tool at their disposal and are comfortable with using of interactive smart phone applications. The required specification for the phone will be determined after completed testing; 6. Ability to read, understand and write Chinese; 7. Beta-blockers naïve or with no Beta-blocker use during the last 1 month  Previous myocardial infarction during the recent 1 year; 2. Cardiac shock or unstable heart failure (NYHA III); 3. SBP<100 mmHg; 4. Sick sinus syndrome; 5. II-III degree atrioventricular block; 6. Existing contraindication for Beta-blockers or allergic to beta-blockers; 7. Participation in another clinical study with a beta blocker during the last 3 months; 8. Inability to sign the informed consent form; 9. Females during pregnancy and lactation and women of child bearing potential planning to be pregnant within 24 weeks.; 10. Patients who withdraw from this study for any reason cannot re-enter the study; 11. Life expectancy < 1 year; 12. Severe asthma or COPD; 13. Severe peripheral vascular disease
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dyspnea Pulmonary Disease Age over 18 years old Able to respond the questionnaire Presenting at admission a dyspnea over 3/10 on numerical analogic scale Admitted for a respiratory cause  cognitive impairment aphasia no french-speaking person
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Dermatitis, Atopic Pruritus Dermatitis Eczema Part A Healthy Volunteers Written informed consent obtained prior to any required study-related procedure Healthy female or male subject aged 18 to 65 Willing to use medically effective methods of birth control Females of reproductive potential must have a negative serum pregnancy test at screening and negative serum or urine pregnancy test prior to first study drug application on Day 1 Non-smoker (no nicotine products for at least 6 months prior to screening) BMI ≥18.5 kg/m2 and ≤32.0 kg/m2 with minimum weight of 60 kg Part B Subjects with AD Written informed consent obtained prior to any required study-related procedure  Both Part A and Part B Pregnant or breast-feeding women Skin disease that may interfere with study assessments Febrile illness within 6 days prior to Day 1, history of cancer within 5 years of Day 1, major surgery within 8 weeks prior to Day1, known immunodeficiencies, positive for hepatitis B or C or HIV infection Significant medical/surgical history or condition or current physical/laboratory/ECG/ vitals signs abnormality that might compromise the subject Corrected QT duration ≥450 milliseconds or other significant ECG abnormality Received marketed or investigational biological agent within 12 weeks prior to Day 1 or JAK inhibitor or nonbiological product or device within 4 weeks of Day 1 or within 8 weeks of Day 1 if investigational product used or any drug/ substance that is a strong inhibitor or inducer of CYP3A4 or CYP2D6 Suspected hypersensitivity/allergy to lidocaine Significant drug or alcohol abuse or mental illness in 2 years prior to Day 1 Part A Only Healthy Volunteers: -Used medications or skin emollients within 2 weeks prior to Day 1 unless approved by investigator and sponsor Part B Only
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Oxidative Stress Morbid Obesity American Society of Anesthesiology score I-III 65 years BMI> 40  American Society of Anesthesiology IV Under 18 years Over 65 years Obstetric patients Uncontrolled diabetes mellitus, cardiovascular and pulmonary disease Cerebrovascular disease Patients who refused informed consent forms
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Hypercholesterolemia Subjects must meet all of the following in order to be included in the study Provide a signed and dated informed consent form Men or women with an age of 18 to 70 years of age at screening (Inclusive) BMI between18kg/m2 and 30kg/m2(Inclusive) Diagnosis of hyperlipidemia, and taking statins with moderate doses or above for at least 4 weeks Fasting LDL-C between 100 mg / dl (2.6 mmol / L) and 220 mg / dl (5.7 mmol / L) at screening (Inclusive) Fasting triglycerides ≤ 400 mg (4.5 mmol / L) at screening  Subjects who do not meet any of the following cannot be included in the study Subject's current statin treatment are stable less than 4 weeks prior to random enrollment New York Heart Association (NYHA) III or IV heart failure, or last left ventricular ejection fraction <30% Uncontrolled hypertension, defined as repeated measurements confirmed, sitting systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg Diabetic patients have one of the following conditions; 1. Known microvascular and macrovascular complications 2. HbA1c>7.5% within 4 weeks before screening Moderate or severe renal insufficiency, defined as the estimated glomerular filtration rate <60 ml / min / 1.73 m2 during screening (calculated using the MDRD formula) Active liver disease or impaired liver function, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the normal upper limit (ULN) at screening Have previously undergone liver transplant surgery Creatine kinase (CK) ≥ 3 times the upper limit of normal (ULN) at screening
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Respiratory Insufficiency Dyspnea Adults over the age of 18 years Demonstrated respiratory distress upon mild to moderate exertion (e.g. dyspnea upon standing, walking, etc.) Candidate for clinical ambulation/mobilization  Hypoxemia at resting baseline: unable to maintain SpO2≥88% with supplemental oxygen Inability to provide informed consent Pregnancy Known contraindication to perform ambulation, per site SOC practices Inadequate respiratory drive or any known contraindications to HVNI Inability to use nasal cannula and HVNI therapy Agitation or uncooperativeness Determined by the attending clinician to be sufficiently unstable or unsuitable for this feasibility study
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 30.0-60.0,  Chronic Obstructive Pulmonary Disease Patient having mild to moderate stage of COPD  Any facial injury and surgery Sinusitis Patient with respiratory failure Patient having dyspnea on cardiac origin Patient having allergic rhinitis and Bronchitis Patients having cystic fibrosis
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 10.0-40.0,  Friedreich Ataxia Molecularly defined FRDA willingness to participate in the study and signing of the informed consent form In order to control for the ongoing deterioration associated with the disease, the investigator will recruit only those patients who had been already studied with the MRI protocol and the functional scales indicated below approxymately 12 months before the beginning of the present study  presence of any contraindication for MRI study presence of clinically significant heart, liver or kidney disease or other medically unstable conditions Known sensitivity to γIFN Previous exposure to recombinant hematopoietin Ongoing use of desferiprone or other specific FRDA treatments Pregnancy or lactation
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Dyslipidemias subjects with prior history of clinical ASCVD 2. subjects with primary elevation of LDL cholesterol ≥190 mg/dL 3. subjects with diabetes, age 40 to 75 years, and LDL cholesterol 70 to 189 mg/dL 4. subjects without diabetes, age 40 to 75 years, LDL cholesterol 70 to 189 mg/dL, and with estimated 10-year ASCVD risk ≥7.5%  history of significant statin-induced rhabdomyolysis or myopathy 2. history of a significant hypersensitivity reaction to rosuvastatin 3. uncontrolled diabetes mellitus (HbA1c >9%) 4. uncontrolled hypertension (systolic blood pressure >190 mmHg or diastolic blood pressure >100 mmHg) 5. current active liver disease (alanine aminotransferase and/or aspartate aminotransferase >2 times the upper limit of normal) 6. chronic kidney disease (serum creatinine clearance <30 ml/min) 7. creatine kinase levels >3 times the upper limit of normal 8. use of prohibited concomitant therapies 9. history of malignancy within the last 5 years 10. women who were pregnant, breast-feeding or of childbearing potential without contraception 11. subjects who would take any medication for purposes other than this trial within 30 days after taking this study's medication
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-60.0,  Simultaneous Pancreas-kidney Transplantation Diabetic Cardiomyopathy patients with type 2 diabetes were treated with SPK; 2.No definite history of cardiovascular diseases (such as congenital heart disease, coronary heart disease, cardiomyopathy or valvular heart disease, etc.); 3. Preoperative hemodialysis 4. No history of heart failure  Contraindications in cardiac magnetic resonance imaging；2.poorly controlled hypertension；3.CMR examination revealed marked hypertrophy of the left ventricular myocardium